Gapping up
In reaction to strong earnings/guidance:
- INGN +24%, NTRI +12.1%, ELVT +9.9%, EFII +9.4%, QTNA +8.1%, THC +5.7%, HLIT +5.5%, ALSN +4.6%, MTZ +4.5%, IDTI +4%, FDP +3.8%, AKAM +3.6%, UAA +3.6%, APTI +3.4%, ADM +3.1%, TNET +2.6%, KAI +2.4%, WCG +2.4%, HEP +2.4%, AEIS +2%, NBIX +1.8%, EDGE +1.8%, MX +1.6%, WLL +1.5%, ETN +1.3%, MRK +1.1%, VRNS +1%, EMR +0.9%, JCI +0.9%, AET +0.5%
Other news:
- KPTI +26.1% (Karyopharm Therapeutics reports 'positive' top-line results from the Phase 2b STORM study evaluating the Company's lead, oral Selective Inhibitor of Nuclear Export (SINE) compound selinexor in heavily pretreated patients with refractory multiple myeloma)
- HCA +4% (ticking higher following THC results)
- KL +1% (identifies potential new source of gold production in Northern Australia)
Analyst comments:
- ROKU +1.4% (initiated with a Overweight at KeyBanc Capital Mkts)
- CTXS +1.2% (added to Conviction Buy List at Goldman)